According to Future Market Insights, the central nervous system lymphoma treatment industry is projected to rise at a steady growth valued at USD 123.2 billion with a 5.2% CAGR until 2033, being valued at USD 205.3 billion.
The rapid advancements in diagnostics and therapeutics of the central nervous system (CNS) disease significantly contribute to market growth. The rising prevalence of central nervous system diseases positively influences the market growth. The rising demand for effective therapeutic options catalyzes market growth.
Pharmaceutical companies are focusing on investing in and developing novel therapies for the treatment of CNS diseases. The surging approval of generic products and the entry of new products into the market favor market growth. The extensive R&D efforts, the introduction of novel drug-delivery systems, and the advancements in the drug-delivery systems bolster the market growth. The introduction of transdermal patches and the presence of strong pipeline products fuels the market growth. The key pharmaceutical players are focusing on treatments to prevent neurological disorders. The increasing awareness regarding mental health drives market growth. The rising awareness regarding neurodegenerative diseases by government and non-government organizations drives market growth.
The process of approval of central nervous system therapeutic and the drugs used to treat central nervous system diseases is very time-consuming. This factor restricts the market growth. Furthermore, research and development require a higher amount of investment which hampers market growth. It is a longer developmental and approval process. The higher cost per approval impedes the central nervous system therapeutic market growth.
The increasing prevalence of neurological disorders offers numerous opportunities for market growth. The rising diagnosis rates in developed and emerging countries significantly contribute to market growth. The governments are focusing on creating awareness regarding these conditions through campaigns. The launch of a new generation of antipsychotic drugs offers lucrative opportunities for market growth.
The innovation of central nervous system treatment drugs and strategic initiatives adopted by key companies operating in the CNS therapeutics market fuels the market growth. The increase in the prevalence and incidence of neurological disorders catalyzes market growth. The growing geriatric population and the growing product launches for treating neurological disorders propel the market growth.
The stringent regulations of the governments challenge the central nervous system therapeutic market growth. The therapeutic drugs used to treat the central nervous system must go through an approval process. This process is very strict, and various stringent regulations are imposed by the government, which further challenges market growth.
Key Takeaways from the Market Study:
- The extensive R&D efforts, the introduction of novel drug-delivery systems, and the advancements in the drug-delivery systems bolster the market growth.
- Process of approval of central nervous system therapeutic and the drugs used to treat central nervous system diseases is very time-consuming, thus restricting the market growth.
- Innovation of central nervous system treatment drugs and strategic initiatives adopted by key companies operating in the CNS therapeutics market fuels the market growth.
- Therapeutic drugs being used in the treatment of the central nervous system must go through an approval process where these stringent regulations of the governments have been imposed as a challenge to the central nervous system therapeutic market growth.
Growing Need for Market Insights: Access Our Full Report for Thorough Analysis and Trends!
Competitive Landscape:
Key players operating in the central nervous system lymphoma market include:
- Amgen
- Dr. Reddy’s laboratories
- Roche
- Bristol-Myers Squibb
- Cipla
- Merck
- Novartis
- AbbVie
- Fresenius SE & Co. KGaA
- Sanofi S.A
Some of the important developments of the key players in the market are:
- In September 2020, Australia-based oncology-focused biotechnology company, Kazia Therapeutics Limited entered into collaboration with US-based Dana-Farber Cancer Institute. This collaboration aimed to investigate the use of paxalisib, a new investigational drug by Kazia Therapeutics in the treatment of the Central Nervous System Lymphoma Market.
- Pembrolizumab is marketed under the trade name Keytruda by Novartis AG. It is used to treat intraocular melanoma as part of cancer immunotherapy, gently injected in the vein. The immune system can combat the cancer cells strengthened by it. Pembrolizumab targets and blocks the activity of PD-1, a protein present on the surface of some immune cells called the T-cells.
Key Segments Profiled in the Central Nervous System Lymphoma Treatment industry Report:
Treatment:
- Chemotherapy
- Radiotherapy
- Steroid therapy
- Targeted therapy
End User:
- Hospitals
- Clinics
- Ambulatory surgical centers
Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East & Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube